Evidence map›Paper›PMID 41305963›Full record

ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026

A Longitudinal Assessment of Endometriosis Patients Prescribed Cannabis-Based Medicinal Products: A Case Series From the UK Medical Cannabis Registry.

Sara Getter, Simon Erridge, John Warner-Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, Shelley Barnes, Alia Darweish Medniuk, Rahul Guru, Wendy Holden and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sara GetterMedical Cannabis Research Group, Imperial College London, London, UK.ORCID 0009-0005-9803-7921
Simon ErridgeMedical Cannabis Research Group, Imperial College London, London, UK.
John Warner-LevyMedical Cannabis Research Group, Imperial College London, London, UK.
Evonne ClarkeCuraleaf Clinic, London, UK.
Katy McLachlanCuraleaf Clinic, London, UK.
Ross CoomberCuraleaf Clinic, London, UK.
Shelley BarnesCuraleaf Clinic, London, UK.
Alia Darweish MedniukCuraleaf Clinic, London, UK.
Rahul GuruCuraleaf Clinic, London, UK.
Wendy HoldenCuraleaf Clinic, London, UK.
Mohammed SajadCuraleaf Clinic, London, UK.
Robert SearleCuraleaf Clinic, London, UK.
Azfer UsmaniCuraleaf Clinic, London, UK.
Sanjay VarmaCuraleaf Clinic, London, UK.
James J RuckerCuraleaf Clinic, London, UK.
Michael PlattCuraleaf Clinic, London, UK.
Mikael H SodergrenMedical Cannabis Research Group, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough there is growing evidence supporting the use of cannabis-based medicinal products (CBMPs) for the management of chronic pain, there is a paucity of data on their effect on endometriosis-associated chronic pain.

aimsThis study aimed to perform an analysis of pain-specific and general health-related quality of life (HRQoL) outcomes for patients with endometriosis-associated chronic pain treated with CBMPs. MATERIALS AND

methodsPrimary outcomes included changes in patient-reported outcome measures (PrOMs) from baseline to 1, 3, 6, 12 and 18 months. A repeated measures ANOVA was applied to assess changes in PrOMs at 1 to 18 months from baseline. Secondary outcomes included incidence and frequency of adverse events (AEs).

resultsSixty-three patients met inclusion criteria. Initiation of CBMPs was associated with improvements in all pain-specific PrOMs from baseline to 18 months (p < 0.050). EQ-5D-5L index value showed improvements between baseline and all months (p < 0.050). Anxiety and sleep quality PrOMs showed improvements from baseline to 18 months (p < 0.050). Minimal clinically significant differences (11%-37%), moderately important improvements (5%-22%) and substantial improvements (0%-11%) were observed in the Brief Pain Inventory (BPI) and pain severity visual analogue scale. Sixty-two adverse events were reported by 16 (25.40%) participants.

conclusionsThis study observed an association between CBMP treatment and improvements in pain and HRQoL in patients with endometriosis. Causality cannot be inferred due to the nature of this observational study; however, these findings provide complementary evidence for the development of randomised controlled trials to assess the efficacy of CBMPs for endometriosis-associated chronic pain.

Indexed as

Chronic PainEndometriosisMedical MarijuanaAdultAnxietyFemaleHumansLongitudinal StudiesMiddle AgedPatient Reported Outcome MeasuresQuality of LifeRegistriesUnited KingdomMedical Marijuanacannabidiolcannabisendometriosispaintetrahydrocannabinol

Identifiers

PMID41305963
PMCPMC12920047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.